KR (2015, on market)
USA (2016), Japan (2018), Hong Kong (2019), Pakistan (2019), Israel (2020), Argentina (2020), Malaysia (2020), EU (2021)
InnoSEAL is mainly used in Interventional Radiology and Cardiology for hemostasis of the radial artery or femoral artery access site following catheterization procedures. InnoSEAL has been launched in number of international markets including EU, USA and Japan.
- Approval status
- KR (2019)
DescriptionInnoSEAL Plus is the very first absorbable hemostatic product incorporating InnoTherapy’s technology. The Korean Ministry of Food and Drug Safety (KMFDS) approved InnoSEAL Plus as a Class IV Medical Device in October 2019.
- Approval status
- KR (2019)
DescriptionEndoSil is an absorbable hemostatic agent used to control gastrointestinal bleeding that may occur during endoscopic surgery. The unique properties of EndoSil enable it to be used as hemostatic agent in areas of the digestive tract that have traditionally posed difficulties because of the nature of mucosal tissues and the secretion of gastric acid.
DescriptionGellySil combines a widely used biomaterial with a proprietary material developed by InnoTherapy to produce an easy-to-use hemostatic agent with a variety of applications. GellySil is anticipated to serve as a versatile product with applications in diverse surgical environments such as laparscopic and endoscopic procedures.
DescriptionFilm-type surgical sealant is used for the complete sealing of anastomosis sites. The tensile strength of the biomaterial combined with the adhesive ability of InnoTherapy’s proprietary material enables sealing of vascular or gastrointestinal anastomosis sites without disturbing blood flow or peristalsis.
DescriptionThe STOP Needle is coated with a proprietary hemostatic agent that can fundamentally block potential hemorrhaging or infections from the puncture site of vascular injections. The STOP Needle is expected to make a significant contribution to controlling and lowering the incidence of hospital-acquired infections to both patients and medical staff.
DescriptionThis version of the STOP Needle has been optimized for use in ophthalmology. The STOP Needle prevents potential leakage of drugs injected into the intraocular space thereby maintaining the intended level of the drug and improving therapeutic efficacy. Among common eye disorders, macular degeneration is a condition for which a large number of companies are developing therapeutic agents; however, drugs that are currently on the market or those under development are all extremely costly. The use of the intraocular STOP Needle is thus expected to reduce the cost of such therapies by allow for a more efficient, targeted application of these drugs.
DescriptionWound dressing patch is being developed via research on novel and unconventional materials. It can be applied to various wounds (chronic wounds, burns, etc.) for the purpose of absorbing would exudate, preventing hemorrhage or loss of body fluid, protecting the wound area, and facilitating healing.
DescriptionOne of the critical challenges of gene therapy is the development of techniques that enable gene therapies to be delivered to the target organ via intravenous injection. Our patented materials can bind to a variety of proteins and be organ-specifically distributed after being systemically injected into the body. Our aim is to leverage the unique features of our proprietary materials to develop a universal delivery platform for gene therapy. We are especially focused on the use of adeno-associated viruses (AAV) as an emerging and promising delivery mechanism for gene therapies.